KALA BIO’s (KALA) “Buy” Rating Reaffirmed at HC Wainwright

KALA BIO (NASDAQ:KALA)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $15.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 118.34% from the company’s previous close.

Separately, Oppenheimer restated an “outperform” rating and set a $15.00 price objective on shares of KALA BIO in a report on Monday, August 19th.

KALA BIO Stock Up 1.6 %

Shares of KALA stock traded up $0.11 on Friday, hitting $6.87. The stock had a trading volume of 8,914 shares, compared to its average volume of 83,799. KALA BIO has a one year low of $4.21 and a one year high of $10.97. The business has a 50 day moving average price of $6.00 and a 200 day moving average price of $6.29. The company has a market cap of $31.67 million, a PE ratio of -0.55 and a beta of -2.13. The company has a quick ratio of 3.07, a current ratio of 2.15 and a debt-to-equity ratio of 3.18.

KALA BIO (NASDAQ:KALA) last announced its earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.43) by $0.50. Research analysts anticipate that KALA BIO will post -11.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP acquired a new stake in KALA BIO, Inc. (NASDAQ:KALA) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO makes up about 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th largest position. SR One Capital Management LP owned 15.76% of KALA BIO at the end of the most recent quarter. Institutional investors own 24.61% of the company’s stock.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.